Arrowhead Pharmaceuticals (ARWR) Appoints Victoria Vakiener to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 2, 2022 7:31 AM EDTPASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022.
Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said, Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines.
Ive watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years, said Ms. Vakiener.... More
